Cerebrospinal fluid (CSF) dynamics are increasingly recognized as central to brain waste clearance. Beyond the classical view of unidirectional CSF circulation, recent studies have identified the glymphatic system and meningeal lymphatic vessels as major complementary pathways. Glymphatic transport is driven by arterial pulsation, respiration, vasomotion, and strongly enhanced during slow-wave sleep. Advances in neuroimaging, including DTI-ALPS, EPVS quantification, contrast-enhanced magnetic resonance imaging (MRI), and ultrafast functional MRI, have enabled in vivo assessment of these mechanisms. Impaired glymphatic function has been linked to neurodegenerative and cerebrovascular diseases, highlighting its clinical relevance. Potential interventions range from lifestyle measures such as sleep optimization, exercise, and vascular risk control, to pharmacological and experimental strategies aiming to modulate CSF flow. These insights open new opportunities to target the glymphatic-lymphatic axis for the prevention and treatment of neurological disorders.

Neuropathic pain markedly impairs quality of life and imposes a substantial socioeconomic burden, while available treatments often provide only partial relief and are limited by safety concerns. The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG-IASP) first published pharmacologic recommendations in 2007, followed by a major update in 2015 and a new guideline in 2025. This narrative review specifically compares the 2015 and 2025 NeuPSIG-IASP guidelines, outlining key methodological changes and therapeutic shifts. The 2025 guideline is based on a larger, more rigorous meta-analysis, maintains α2δ-ligands (adds mirogabalin), serotonin-noradrenaline reuptake inhibitors, and tricyclic antidepressants as first-line drugs, downgrades tramadol into the opioid third-line group. It also introduces high-frequency motor-cortex repetitive transcranial magnetic stimulation as a weakly recommended third-line option and discusses implications for Korean clinical practice.

Spontaneous intracranial hypotension (SIH) is an underrecognized cause of secondary headache resulting from spinal cerebrospinal fluid (CSF) leakage. Although traditionally considered a benign and self-limiting condition, SIH is now known to be associated with substantial disability and potentially serious complications when diagnosis and treatment are delayed. The clinical presentation is heterogeneous, often leading to misdiagnosis and prolonged diagnostic latency. Recent advances have shifted the conceptual framework of SIH from a simple reduction in CSF pressure to a disorder of CSF volume depletion with distinct etiologic subtypes, including ventral dural tears, lateral dural defects associated with meningeal diverticula, and CSF-venous fistulas. Accordingly, diagnostic strategies have evolved toward a stepwise integration of clinical history with targeted imaging modalities. Contrast-enhanced brain magnetic resonance imaging (MRI) and whole-spine MRI serve as essential initial tools to establish the diagnosis and assess complications, while dynamic myelographic techniques such as digital subtraction myelography and dynamic or decubitus computed tomography myelography play a critical role in localizing the site and mechanism of CSF leakage. Management of SIH has similarly progressed toward subtype- based, individualized treatment. Epidural blood patching remains the mainstay of initial therapy, but its effectiveness varies depending on leak type and chronicity. In selected patients, surgical repair or endovascular embolization offers definitive treatment. This review summarizes current concepts in the diagnosis and management of SIH and proposes a practical diagnostic and therapeutic algorithm, while also addressing unmet needs and real-world limitations within the Korean healthcare system.

Background/Aims: The optimal vascular access strategy for very elderly patients initiating hemodialysis (HD) remains unclear. Arteriovenous fistulas (AVFs) offer long-term benefits but may be limited due to vascular aging. This study evaluated vascular access outcomes in patients aged ≥ 80 years. Methods: We conducted a retrospective cohort study using data from the Korean National Health Insurance Service between 2008 and 2019. Patients aged ≥ 80 years who initiated HD with a newly created AVF or arteriovenous graft (AVG) were included. Primary outcomes were primary, assisted primary, and secondary patency. The secondary outcome was all-cause mortality. Outcomes were compared using Kaplan–Meier analysis and multivariable Cox regression. Results: Among 8,487 patients, 5,124 (60.4%) received AVFs (AVF group) and 3,363 (39.6%) received AVGs (AVG group). AVFs were associated with significantly lower rates of patency loss across all definitions. The adjusted hazard ratios (HRs) for AVG vs. AVF were 1.76 (95% confidence interval [CI], 1.67–1.86) for primary patency loss, 1.90 (95% CI, 1.77–2.03) for assisted primary, and 3.18 (95% CI, 2.81–3.61) for secondary patency loss. All-cause mortality was also higher in the AVG group (adjusted HR, 1.24; 95% CI, 1.17–1.30). Conclusions In this large-scale study, AVF use was associated with superior patency and lower mortality compared with AVG in patients aged ≥ 80 years. These findings suggest that AVF remains a beneficial option for appropriately selected elderly patients and that age alone should not be a primary barrier to its creation.

Background: Enzyme immunoassays (EIAs), which detect glutamate dehydrogenase (GDH) and toxin A/B, are widely used to screen for Clostridioides difficile infection (CDI); however, their sensitivity is lower than that of molecular assays. This study aimed to evaluate the performance of two EIAs, C. Diff Quik Chek Complete (QCC) and RIDASCREEN (RIDA), and investigate the cycle threshold (Ct) values from two real-time polymerase chain reaction (PCR) assays (Allplex GI–Bacteria(I) and Xpert C. difficile) in EIA-discordant samples. Methods: A total of 180 clinical stool samples were tested using QCC, RIDA, and Allplex GI– Bacteria(I) PCR assays. The Xpert C. difficile assay was used to analyze discordant results. Results: QCC and RIDA showed high sensitivities for GDH detection, 100.0% and 94.4%, respectively. QCC was significantly more sensitive than RIDA for toxin detection (51.4% vs. 28.6%, p = 0.007). In 25 EIA-discordant, Xpert positive samples, the Ct values of the toxin B gene ranged from 31.5 to 44.8 (mean, 38.1) for Allplex PCR and from 23.7 to 36.3 (mean, 30.4) for Xpert PCR. The Ct values of the two PCR assays were not significantly correlated (r = 0.201, p = 0.324). Conclusion QCC is a suitable initial immunological test for diagnosing CDI. The lack of correlation in the Ct values between the two real-time PCR assays suggests that assay-specific validation is necessary for cutoff level interpretation.

Background: A novel botulinum toxin type A (Protoxin; Protox Inc.) has been developed. Objective: To evaluate the efficacy and safety of the newly developed Protoxin compared to the approved drug onabotulinumtoxinA (OBoNT) in moderate to severe glabellar lines. Methods: Adults with a glabellar line Facial Wrinkle Scale (FWS) score of 2 (moderate) or 3 (severe) were enrolled in the study. Subjects were randomized in a 1:1 ratio to receive either Protoxin or OBoNT. A total of 20 units of botulinum toxin was injected at five sites in the glabellar region (4 units at each site). FWS scores were assessed at baseline and at weeks 4, 8, 12, and 16 post-injection. The primary endpoint was the proportion of subjects at week 4 who had a reduction of 2 or more points in FWS and a final score of 0 (none) or 1 (mild). Results: A total of 274 subjects were randomized, of whom 78.1% were female. At week 4 post-treatment, the improvement rate of glabellar lines was 62.22% in the Protoxin group and 62.96% in the OBoNT group. The lower limit of the two-sided 95% confidence interval (−12.24%) exceeded the −15% margin, confirming the non-inferiority of the new drug. Safety profiles were comparable between the two groups. Conclusion Protoxin demonstrated efficacy and safety profiles comparable to those of OBoNT in the treatment of moderate to severe glabellar lines.

Background: Many smart care technologies have been developed recently, but it remains unclear which of them are necessary for use in long-term care hospitals (LTCHs). Methods: A total of 114 physicians, registered nurses (RNs), nurse assistants (NAs), and care assistants (CAs) from eight LTCHs completed a survey assessing perceived needs for 10 smart care technologies using 5-point Likert scales. One-sample t-tests, one-way ANOVA with Scheffé post-hoc tests, Friedman tests, and simple linear regression were used to examine differences by occupation and hospital characteristics. Additionally, focus group interviews with 10 participants were done. Results: Mean perceived need for smart care technologies was 3.99, with the highest ratings for smart mattresses (4.14), all-in-one patient transfer robots (4.09), and smart monitoring systems (4.06). Regarding the most preferred by occupation, physicians chose smart monitoring systems (4.19) and leg-care devices (4.19), RNs chose smart mattresses (4.11), NAs chose radar-based fall detection devices (4.22), and CAs chose all-in-one patient transport robots (4.36). Perceived need for smart care technologies was higher in LTCHs with lower monthly family fees and in those without a rehabilitation service, explaining 42.8% and 10.8% of the variability, respectively. Conclusion Smart care technologies were seen as necessary in LTCHs, but the types of technologies considered most important differed by occupational role and hospital characteristics.

Background: Older patients aged ≥75 years are underrepresented in major statin trials, leaving the optimal statin intensity after acute ischemic stroke (AIS) undefined. We aimed to compare functional outcomes and short-term safety between high-intensity statin therapy (HIST) and moderate-intensity statin therapy (MIST) in patients aged ≥75 years with AIS or transient ischemic attack. Methods: Using a prospective stroke registry at a single tertiary center (2019–2022), we retrospectively analyzed 337 patients aged ≥75 years with AIS or transient ischemic attack who maintained statin therapy for 3 months (HIST n=117; MIST n=220). The primary outcome was a favorable 3-month functional outcome (modified Rankin Scale score 0–2). Secondary outcomes included stroke recurrence, adverse effects, and statin discontinuation. Multivariable logistic regression with pre-specified sensitivity analyses was performed. Results: Favorable outcomes at 3 months were more frequent with HIST (70.9% vs. 55.9%; p=0.010). After multivariable adjustment, HIST was independently associated with a favorable outcome (adjusted odds ratio [aOR]=2.03, 95% confidence interval [CI] 1.17–3.53), consistent across sensitivity analyses: per-protocol (aOR=3.48, 95% CI 1.97–6.17) and atrial fibrillation-adjusted (aOR=2.21, 95% CI 1.26–3.89). No significant differences were observed in statin discontinuation, stroke recurrence, or adverse effects. Conclusion In older patients with AIS, HIST was independently associated with better functional outcomes without evidence of increased harm, broadly consistent with current guideline recommendations for HIST when tolerated. Prospective studies are needed to confirm a causal relationship.